Senate Medicaid Reform Bill Could Mean More Whistleblowers At State Level
Executive Summary
A provision in the Senate's Medicaid reform bill that encourages states to pass qui tam laws could increase incentives for whistleblowers to file suits against pharmaceutical companies alleging rebate fraud
You may also be interested in...
Off-Label Dissemination Keeps FDA Stuck Between Prosecutors And Firms
As industry weighs the potential impact of FDA's guidance on good reprint practices, stakeholders are suggesting alternate policy approaches that could give companies sufficient clarity on how to conduct off-label dissemination
Off-Label Dissemination Keeps FDA Stuck Between Prosecutors And Firms
As industry weighs the potential impact of FDA's guidance on good reprint practices, stakeholders are suggesting alternate policy approaches that could give companies sufficient clarity on how to conduct off-label dissemination
Rx Compliance Enforcement Is Moving Away From “FDA” Cases, Sheehan Says
CAMBRIDGE, Mass.-Due to FDA's diminishing influence over the direction of pharmaceutical regulatory enforcement, a comprehensive understanding of the compliance concerns for drug products should focus on existing case law to understand the dynamics of the enforcement landscape, New York Medicaid Inspector General James Sheehan said